S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

SABS SAB Biotherapeutics Inc

3.62

0.36 (11.04%)

02 Nov 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

SAB Biotherapeutics (NASDAQ:SABS)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more SAB Biotherapeutics Charts.

SAB Biotherapeutics (NASDAQ:SABS)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more SAB Biotherapeutics Charts.

SAB Biotherapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 14 August 2024 (3 months ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Tuesday 13 August 2024 (3 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 9 August 2024 (3 months ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Thursday 1 August 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 31 July 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (4 months ago) • Edgar (US Regulatory)

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
Tuesday 21 May 2024 (5 months ago) • GlobeNewswire Inc.

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
Monday 6 May 2024 (6 months ago) • GlobeNewswire Inc.

SAB Biotherapeutics Provides SAB-142 Trial Update
Tuesday 16 April 2024 (7 months ago) • GlobeNewswire Inc.

More SAB Biotherapeutics Inc News Articles

Vontobel Financial Produ...

Societe Generale Effekten

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions